MedTrace Logo

A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis.

NCT01262534 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1042

Last updated 2013-05-06

No results posted yet for this study

Summary

The purpose of this study is to assess the clinical profile of patients with moderate to severe psoriasis in Spain. The primary objective is to analyze the clinical profile of patients with moderate to severe psoriasis, as defined by a set of conditions (obesity, hypertension, diabetes, abnormal amounts of lipids in the blood, cardiovascular disease, etc.) and its correlation to the patients' quality of life. The secondary objectives are to describe the demographic characteristics and habits of the patient, to evaluate the clinical characteristics of the disease, and to describe the diagnostic and therapeutic procedures being used in standard clinical practice and the patients' expectations for these therapies.

Conditions

Interventions

OTHER

Clinical profile of patients

Comorbidities and associated type of treatments will be collected.

OTHER

Patient Preferences about treatment

Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.

OTHER

Quality of Life

The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).

Sponsors & Collaborators

  • Janssen-Cilag, S.A.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag S.A. (formerly Janssen Sp) Clinical Trial · Janssen-Cilag, S.A.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-06-30
Completion
2011-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01262534 on ClinicalTrials.gov